Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have earned an average rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $31.33.

KURA has been the topic of a number of recent research reports. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, May 3rd. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, June 24th. Finally, JMP Securities restated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Tuesday, June 18th.

Kura Oncology Stock Up 1.5 %

NASDAQ:KURA opened at $19.14 on Friday. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $20.84 and a 200-day moving average of $20.63. The firm has a market capitalization of $1.46 billion, a PE ratio of -8.82 and a beta of 0.88. Kura Oncology has a 52 week low of $7.41 and a 52 week high of $24.17.

Insider Activity

In other Kura Oncology news, insider Teresa Brophy Bair sold 2,615 shares of Kura Oncology stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $22.15, for a total transaction of $57,922.25. Following the transaction, the insider now directly owns 68,979 shares in the company, valued at approximately $1,527,884.85. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 5.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC boosted its position in Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after purchasing an additional 1,449 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Kura Oncology during the 1st quarter valued at about $110,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Kura Oncology by 352.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock valued at $124,000 after buying an additional 6,692 shares in the last quarter. Saxon Interests Inc. acquired a new position in Kura Oncology in the first quarter worth approximately $201,000. Finally, Entropy Technologies LP bought a new position in Kura Oncology during the first quarter valued at approximately $218,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.